MediciNova looks to ride NASH wave with Phase II start
This article was originally published in Scrip
The US venture MediciNova is apparently attempting to make the most of recent investor and medical interest in non-alcoholic steatohepatitis (NASH) therapies by announcing plans to start clinical trials in this indication for one of its dormant pipeline molecules.
You may also be interested in...
Partners say they are encouraged by new overall response data from early trials for the two drugs together in kidney and liver cancer, presented to ASCO.
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.